-
Nov 17, 2023
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Nov 07, 2023
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
-
Oct 31, 2023
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
-
Oct 31, 2023
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
-
Oct 20, 2023
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Oct 16, 2023
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
-
Sep 27, 2023
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
-
Sep 22, 2023
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Sep 14, 2023
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
-
Sep 07, 2023
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
-
Aug 18, 2023
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Aug 08, 2023
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
-
Jul 25, 2023
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
-
Jul 24, 2023
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
-
Jul 21, 2023
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Jul 13, 2023
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
-
Jul 10, 2023
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
-
Jul 10, 2023
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
-
Jul 10, 2023
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
-
Jun 20, 2023
Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
-
Jun 15, 2023
Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma
-
Jun 09, 2023
Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
-
May 26, 2023
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
-
May 09, 2023
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
-
May 02, 2023
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
-
Apr 24, 2023
Iovance Biotherapeutics to Present at Upcoming Conferences
-
Mar 24, 2023
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
-
Mar 01, 2023
Iovance Biotherapeutics to Present at Upcoming Conferences
-
Feb 28, 2023
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
-
Feb 21, 2023
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
-
Jan 23, 2023
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates